On January 16, Longsheng Pharmaceutical announced that the Group expects to record a profit attributable to owners of the company of approximately US$8.
1 million for the year ended December 31, 2022, an increase of approximately US$7.
2 million compared with the same period of the previous year, a growth rate of approximately 798%.
According to the announcement, the profit increase was mainly due to the initial results of the Group's sales strategy adjustment and management structure restructuring for the sinking of the terminal market and the increase of hospital coverage, which led to an increase in sales and gross profit; and last year's profit attributable to owners of the company was a small profit, and if the operating profit for FY2022 is compared with last year's, it is expected to grow by about 155%.
After the release of Yingxi, Langsheng Pharmaceutical rose more than 27% intraday, reaching a high of HK$1.
88, a new high
since October 2021.
Data show that as of the close on January 13, 2023, Langsheng Pharmaceutical closed at HK $1.
47, up 0.
0%, with a turnover rate of 0.
02%, a volume of 67,000 shares and a turnover of HK $
96,800.
Investment banks do not pay much attention to the stock, and no investment bank has rated it within 90 days
.
According to the information, Langsheng Pharma was listed on the main board of the Hong Kong Stock Exchange on May 7, 2010, and is a Hong Kong investment holding company
mainly engaged in pharmaceutical business.
It owns and operates two modern production plants in Ningbo, China, covering an area of about 71,000 square meters and a total construction area of about 36,600 square meters, specializing in the research and development, production and sales of traditional Chinese medicine and chemicals, the main products involve rheumatology, dermatology, medical cosmetology, plant extraction and other fields
.
The company operates
through three divisions.
The specialty drug division is engaged in the development, production and sales
of specialized drugs in the field of rheumatology and dermatology.
Its core specialty drugs include pavlin, leflunomide tablets and mycophenolate mofetil dispersible tablets
.
The plant extraction and health care products division is engaged in the development, production and sales
of traditional Chinese medicine extracts and health care products.
The Other Pharmaceutical Division is engaged in other drug-related businesses
.
The company has a total of three API production lines, a modern Chinese medicine extraction line, a solid preparation workshop, a liquid preparation workshop and a paste workshop
.
It is reported that Ningbo Langsheng Pharmaceutical Co.
, Ltd.
is a professional pharmaceutical sales company
under Langsheng.
At present, the company has established a pharmaceutical marketing network with Ningbo as the center, Shanghai and Beijing as the two sub-centers, radiating the whole country, mainly engaged in rheumatology, dermatology and other related fields of product sales
.
The company's main products are Pavlin, Xinzhiqode, Yahao, Bazhen granules, compound licorice oral solution and other prescription and OTC products
.
={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"share:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body).
appendChild(createElement('script')).
src='http://bdimg.
share.
baidu.
com/static/api/js/share.
js?v=89860593.
js?cdnversion='+~(-new Date()/36e5)]; 
